



BREAKTHROUGH PEPTIDE THERAPEUTICS

7 December 2018

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(e) OF THE CORPORATIONS ACT 2001

This Notice is given by Phylogica Limited (ACN 098 391 961) (“Phylogica”) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (“The Act”).

Phylogica has issued a total of 157,833,334 ordinary fully paid shares, and 10,000,000 unlisted options, under the Company’s 15% capacity under Listing Rule 7.1, without disclosure under Part 6D.2 of the Corporations Act.

Phylogica gives notice under section 708A(5)(e) of the Act that:

- as a disclosing entity, Phylogica is subject to regular reporting and disclosure obligations;
- as at the date of this notice, Phylogica has complied with the provisions of Chapter 2M as they apply to Phylogica and section 674 of the Act; and
- as at the date of this notice, there is no information that is ‘excluded information’ within the meaning of section 708A(7) and 708A(8) of the Act which is required to be disclosed by Phylogica under section 708A(6)(e) of the Act

Kevin Hart
Company Secretary